Last reviewed · How we verify
Desonide Cream 0.05%
Desonide Cream 0.05%, marketed by Promius Pharma, LLC, is a topical corticosteroid with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term patent protection. The primary risk is the potential increase in competition following the 2028 patent expiry.
At a glance
| Generic name | Desonide Cream 0.05% |
|---|---|
| Also known as | Desowen® cream |
| Sponsor | Promius Pharma, LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Alternation in the Human Microbiome With Commonly Used Topical Medications (PHASE1)
- 8-Week Atopic Dermatitis (AD) Treatment Study (PHASE3)
- Evaluation of the Vasoconstriction Properties of MC2-01 Cream (PHASE1)
- Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis (PHASE4)
- Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis (PHASE4)
- Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis (PHASE3)
- Photoaging Treatment With Imiquimod (NA)
- Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Desonide Cream 0.05% CI brief — competitive landscape report
- Desonide Cream 0.05% updates RSS · CI watch RSS
- Promius Pharma, LLC portfolio CI